Company profile
AcuityBio company profile
AcuityBio was founded by Mark Grinstaff, Ph.D., Alain Hanover, M.S., Jesse Wolinsky, Ph.D., and John 'Jay' Schwartz, Ph.D. in late 2009 to commercialize novel polymer drug delivery technologies to treat various types early stage, soft tissue cancers. AcuityBio's lead product candidate aimed at preventing the recurrence of non-small cell lung cancer is based on a synthetic polymer technology invented by co-founders Professor Mark Grinstaff, Ph.D. and Jesse Wolinsky, Ph.D. at Boston University (BU), Departments of Biomedical Engineering and Chemistry. AcuityBio is a privately-held company based in the Greater Boston area.
Business identity
- Website
- https://www.acuitybio.com
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00011-00050 employees
- Revenue range
- $0+
- Founded
- 2009-01-01
Headquarters
- Headquarters
- Calumet City, Illinois, United States
- Postal code
- 02460
- Country code
- US
- Continent
- North America